Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 3, 2012, Pages 669-676

  Digby, Janet E ^a   Martinez, Fernando ^b   Jefferson, Andrew ^a   Ruparelia, Neil ^a   Chai, Joshua ^a   Wamil, Malgorzata ^a   Greaves, David R ^b   Choudhury, Robin P ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

atherosclerosis; cholesterol lowering drugs; macrophages; receptors; vascular biology

Indexed keywords

ACIPIMOX; CYCLOOXYGENASE 2 INHIBITOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERLEUKIN 6; LAROPIPRANT; LIPOPOLYSACCHARIDE; LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NICOTINIC ACID; PROSTAGLANDIN D2; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL STRAIN; CHEMOTAXIS; CYTOKINE RELEASE; DYSLIPIDEMIA; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; LISTERIA MONOCYTOGENES; MONOCYTE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; CELL ADHESION; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; CYCLOOXYGENASE 2 INHIBITORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; I-KAPPA B KINASE; INFLAMMATION; INFLAMMATION MEDIATORS; INTEGRIN ALPHA4BETA1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MONOCYTES; NIACIN; PHOSPHORYLATION; PYRAZINES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, IMMUNOLOGIC; RECEPTORS, NICOTINIC; RECEPTORS, PROSTAGLANDIN; RNA INTERFERENCE; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84857648400     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.241836     Document Type: Article

References (42)

1. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255. (Pubitemid 17208898)
2. Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I, Digby JE, Bannister T, Handa A, Wiesmann F, Durrington PN, Channon KM, Neubauer S, Choudhury RP. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54:1787-1794.
3. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113-2122.
4. Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL. Niacin stimulates adiponectin secretion through the GPR109a receptor. Am J Physiol Endocrinol Metab. 2009;296:E549-E558.
5. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S. PUMA-g and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003;9:352-355. (Pubitemid 36362793)
6. Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury RP. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis. 2010;209:89-95.
7. Knowles HJ, Poole RT, Workman P, Harris AL. Niacin induces PPArαexpression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol. 2006;71:646-656. (Pubitemid 43121998)
8. Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol. 2006;126:2637-2646. (Pubitemid 44764048)
9. Kostylina G, Simon D, Fey MF, Yousefi S, Simon HU. Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109a). Cell Death Differ. 2008;15:134-142. (Pubitemid 350286181)
10. Choudhury RP, Lee JM, Greaves DR. Mechanisms of disease: Macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med. 2005;2:309-315. (Pubitemid 40852635)
11. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109a expressed by immune cells. J Clin Invest. 2011;121:1163-1173.
12. Jefferson A, Wijesurendra RS, McAteer MA, Digby JE, Douglas G, Bannister T, Perez-Balderas F, Bagi Z, Lindsay AC, Choudhury RP. Molecular imaging with optical coherence tomography using ligandconjugated microparticles that detect activated endothelial cells: Rational design through target quantification. Atherosclerosis. 2011;219:579-587.
13. Zhang FX, Kirschning CJ, Mancinelli R, Xu XP, Jin Y, Faure E, Mantovani A, Rothe M, Muzio M, Arditi M. Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem. 1999;274:7611-7614.
14. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, Egido J. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253-261. (Pubitemid 29512257)
15. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-κB transcription factor. Mol Cell Biol. 1990;10: 2327-2334.
16. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-κis a negative regulator of macrophage activation. Nature. 1998;391:79-82. (Pubitemid 28079218)
17. Thorp E, Subramanian M, Tabas I. The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis. Eur J Immunol. 2011;41:2515-2518.
18. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of an extended-release niacin (niaspan): A long-term study. Am J Cardiol. 1998;82:74U-81U; discussion 85U-86U. (Pubitemid 29044485)
19. Digby JE, Lee JM, Choudhury RP. Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol. 2009;20:321-326.
20. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2α/βmice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897. (Pubitemid 28410911)
21. Bursill CA, Choudhury RP, Ali Z, Greaves DR, Channon KM. Broadspectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein e-knockout mice. Circulation. 2004;110:2460-2466. (Pubitemid 39407354)
22. Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, Cybulsky MI, Smith JD. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol. 2001;21:1662-1667. (Pubitemid 34215588)
23. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell. 1990;60:577-584.
24. Alon R, Kassner PD, Carr MW, Finger EB, Hemler ME, Springer TA. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol. 1995;128:1243-1253.
25. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673-687. (Pubitemid 35283958)
26. Chigaev A, Waller A, Zwartz GJ, Buranda T, Sklar LA. Regulation of cell adhesion by affinity and conformational unbending ofβ4α1 integrin. The J Immunol. 2007;178:6828-6839. (Pubitemid 46847408)
27. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. Ppar-κand ppar-κactivators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58. (Pubitemid 32095642)
28. Rubic T, Trottmann M, Lorenz RL. Stimulation of cd36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochemical Pharmacology. 2004;67:411-419. (Pubitemid 38236129)
29. Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM, Chen JR, Muehlbauer MJ, Whalen EJ, Lefkowitz RJ. Beta-arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest. 2009;119:1312-1321.
30. Hanson J, Gille A, Zwykiel S, Lukasova M, Clausen BE, Ahmed K, Tunaru S, Wirth A, Offermanns S. Nicotinic acid-and monomethyl fumarateinduced flushing involves GPR109a expressed by keratinocytes and cox-2-dependent prostanoid formation in mice. J Clin Invest. 2010;120:2910-2919.
31. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101:625-630.
32. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009;104:74-81.
33. Gosset P, Pichavant M, Faveeuw C, Bureau F, Tonnel AB, Trottein F. Prostaglandin D2 affects the differentiation and functions of human dendritic cells: impact on the T cell response. Eur J Immunol. 2005;35:1491-1500. (Pubitemid 40691431)
34. Meyers CD, Liu P, Kamanna VS, Kashyap ML. Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis. 2007;192:253-258. (Pubitemid 46726325)
35. Carlson LA, Hanngren A. Initial distribution in mice of 3H-labeled nicotinic acid studied with autoradiography. Life Sci. 1964;3:867-871.
36. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105:1158-1161. (Pubitemid 34225814)
37. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104:3103-3108. (Pubitemid 34014065)
38. Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, Feldmann M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation. 2009;120:2462-2469.
39. Cole JE, Navin TJ, Cross AJ, Goddard ME, Alexopoulou L, Mitra AT, Davies AH, Flavell RA, Feldmann M, Monaco C. Unexpected protective role for toll-like receptor 3 in the arterial wall. Proceedings of the National Academy of Sciences. 2011;108:2372-2377.
40. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009;202:68-75.
41. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010;30:968-975.
42. Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, Hiyama H, Matsuo A, Matsushime H, Furuichi K. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 2003; 303:364-369. (Pubitemid 36338250)